Do you work with FFPE tissue? MT Group sites have collected thousands of FFPEs for translational studies across indications, therapies, tissue types, and geographies. We’ve collected both common cases as well as rare ones such as:
- Metastatic bladder cancer patients who had failed one or more systemic therapy regimens before tissue collection
- Castration-resistant prostate cancer patients then went on to develop metastatic disease
- Cancer patients that were collected after receiving immuno-oncology (IO) therapeutics
- Diffuse large B-cell lymphoma (DLBCL) patients that were collected both before R-CHOP therapy and after / on R-CHOP therapy
For all of these collections, “MT Level” clinical metadata is the norm, enabling researchers to compare their bench results with clinical profiles.